Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Evaluate Vantage Homepage
  3. Pharmaceutical Companies
  4. Poseida Therapeutics
Thumbnail
January 10, 2022

A late Christmas present for Allogene

US clinical hold over Allogene’s entire pipeline has just been lifted.

Thumbnail
December 15, 2021

Ash 2021 movers – IGM steals the show, for all the wrong reasons

At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.

Article image
Vantage logo
November 08, 2021

Ash 2021 preview – as competition grows Autolus monetises

Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.

Article image
Vantage logo
October 13, 2021

Crispr’s reminder about allogeneic Car-T redosing

Crispr follows Allogene with backing for off-the-shelf Car-T therapy – and adds big concerns over lack of durability.

Article image
Vantage logo
October 08, 2021

Allogene raises the spectre of a Car-T nightmare

Little is known about yesterday’s clinical hold on Allogene’s entire pipeline, but chromosomal abnormalities hint at a worst-case scenario.

Article image
Vantage logo
July 28, 2021

Amgen doubles down on bispecifics, courtesy of Teneobio

Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.

Article image
Vantage logo
April 16, 2021

Precision’s itinerant Car-T cells go on another journey

The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?

Article image
Vantage logo
December 09, 2020

Ash 2020 movers – shorts roasting on an open fire

IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.

Article image
Vantage logo
December 07, 2020

Ash 2020 – US academics target the Car-T relapse problem

Article image
Vantage logo
November 26, 2020

Ash 2020 cell therapy preview – the battle for recognition

With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.

Article image
Vantage logo
November 20, 2020

Precision’s Arcus gets a second endorsement

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.